Tsumura, Japan's leading Kampo medicine maker, announced an upward revision to its forecast for the fiscal year ending March 2027 on the 28th, sending its stock higher as trading resumed.
Tsumura announced an upward revision to its forecast for the fiscal year ending March 2027, prompting a rebound in its stock price. The stock is seeing its first sharp rebound in three days, with buying prevailing.
In afternoon trading, Tsumura's stock rose to ¥3,771, up ¥78, or 2.1%, from the previous day. It briefly climbed as high as ¥3,795.
The reasons for the upward revision and details of the figures are not stated in the report, but investors appear to be watching the content of the new forecast closely.